Caregen Co.Ltd (214370) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caregen Co.Ltd (214370) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.16 Billion ≈ $2.82 Million USD) by net assets (₩216.88 Billion ≈ $146.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Caregen Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Caregen Co.Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Caregen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caregen Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenyang Jinbei Automotive Co Ltd
SHG:600609
|
0.204x |
|
Sunway Co Ltd
SHG:603333
|
-0.019x |
|
Eagle Bancorp Inc
NASDAQ:EGBN
|
-0.030x |
|
Butterfly Network Inc
NYSE:BFLY
|
-0.014x |
|
Boozt AB
ST:BOOZT
|
0.379x |
|
Sumber Tani Agung Resources Tbk PT
JK:STAA
|
0.115x |
|
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
|
N/A |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
0.123x |
Annual Cash Flow Conversion Efficiency for Caregen Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Caregen Co.Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Caregen Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩222.98 Billion ≈ $151.11 Million |
₩13.49 Billion ≈ $9.14 Million |
0.060x | -51.93% |
| 2023-12-31 | ₩227.30 Billion ≈ $154.04 Million |
₩28.60 Billion ≈ $19.38 Million |
0.126x | +198.20% |
| 2022-12-31 | ₩215.98 Billion ≈ $146.37 Million |
₩-27.68 Billion ≈ $-18.76 Million |
-0.128x | -151.82% |
| 2021-12-31 | ₩209.72 Billion ≈ $142.12 Million |
₩51.86 Billion ≈ $35.14 Million |
0.247x | +64.84% |
| 2020-12-31 | ₩205.16 Billion ≈ $139.03 Million |
₩30.78 Billion ≈ $20.86 Million |
0.150x | -53.27% |
| 2019-12-31 | ₩217.01 Billion ≈ $147.06 Million |
₩69.66 Billion ≈ $47.21 Million |
0.321x | +1063.53% |
| 2018-12-31 | ₩204.75 Billion ≈ $138.76 Million |
₩-6.82 Billion ≈ $-4.62 Million |
-0.033x | -116.13% |
| 2017-12-31 | ₩231.83 Billion ≈ $157.11 Million |
₩47.88 Billion ≈ $32.45 Million |
0.207x | +403.39% |
| 2016-12-31 | ₩234.11 Billion ≈ $158.65 Million |
₩-15.94 Billion ≈ $-10.80 Million |
-0.068x | -1180.76% |
| 2015-12-31 | ₩248.87 Billion ≈ $168.66 Million |
₩1.57 Billion ≈ $1.06 Million |
0.006x | -- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more